Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study

BACKGROUND: There is a lack of head-to-head studies comparing the efficacy of fingolimod (FIN) and natalizumab (NTZ) as second-line therapy for relapsing-remitting multiple sclerosis (RRMS). METHODS: Multicenter, observational study, in which, information of 388 patients randomly selected and treate...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Eur Neurol
Prif Awduron: Meca-Lallana, José, Ayuso, Teresa, Martínez-Yelamos, Sergio, Durán, Carmen, Contreras Martín, Yessica, Herrera Navarro, Nicolás, Pérez Sempere, Angel, Álvarez-Cermeño, Jose C., Millán Pascual, Jorge, Meca-Lallana, Virginia, Romero Sevilla, Raúl, Ricart, Javier
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: S. Karger AG 2020
Pynciau:
Clinical Neurology: Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7265769/
https://ncbi.nlm.nih.gov/pubmed/32187609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000505778
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg